Valeant Announces Second-Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Pharma (VRX) Reports Q2 Loss of $0.11, Adj-EBITDA Beats; Maintains FY EPS, Lowers FY Revs
August 8, 2017 7:06 AM EDTValeant Pharma (NYSE: VRX) reported Q2 EPS of ($0.11), versus ($0.88) reported last year. Revenue for the quarter came in at $2.23 billion, versus $2.42 billion reported last year.
Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 million, beating consensus of $910.8 million.
Second-Quarter 2017 Financial Results
Revenues of $2.233... More